1. Market Research
  2. > Pharmaceutical Market Trends
Indonesia Pharmaceutical Market Outlook to 2022 - By Therapeutic Segment, By Domestic and International Players, By Generic and Patent Drugs, By OTC & Prescription Drugs, By Region

Indonesia Pharmaceutical Market Outlook to 2022 - By Therapeutic Segment, By Domestic and International Players, By Generic and Patent Drugs, By OTC & Prescription Drugs, By Region

  • February 2018
  • 118 pages
  • ID: 5472759
  • Format: PDF
  • By Ken Research Private Limited

Summary

Table of Contents

The report titled "Indonesia Pharmaceutical Market Outlook to 2022 - By Therapeutic Segment (Anti-Infectives, Gastrointestinal and Metabolism, Cardiovascular System, Central Nervous System, Respiratory, Musculoskeletal, Dermatology, Genitourinary and Hormones, Blood, Oncology), By Domestic and International Players, By Generic and Patent Drugs, By OTC and Prescription Drugs, By Region" provides information on market size for Indonesia Healthcare and pharmaceutical.



The report covers aspects such as healthcare market segment (by hospitals, pharmaceuticals, medical devices and clinical laboratory), pharmaceutical market segment (by therapeutic segment, by domestic and international players, by generic and patented drug, by OTC and prescription drugs, by domestic sales and exports and by region), competitive landscape of major players in the Indonesia pharmaceutical market, and covering competitive landscape of major pharmaceutical companies including PT Kalbe Farma, PT Sanbe Farma, PT SOHO Global Health, PT Dexa Medica, PT Pharos, PT Kimia Farma, PT Tempo Scan Pacific Tbk, PT Merck Tbk, Fahrenheit, Sanofi Aventis, PT. Novell Pharmaceutical Laboratories, Biofarma, Darya Varia and Konimex. The report concludes with market projection for future and analyst recommendations highlighting the major opportunities and cautions.


 
Indonesia Pharmaceutical Market
Indonesia Pharmaceutical market has registered an increase in the revenue at a CAGR of ~% from USD ~ billion in 2012 to USD ~ billion in 2017.


 
By Therapeutic Segment: Anti-infective drug sale has contributed to the largest share of ~% in the revenue share of Indonesia Pharmaceutical industry in 2017. This is mainly due to high prevalence of bacterial and communicable diseases. This is followed by Gastrointestinal and metabolism drugs with ~%, cardiovascular system drugs with ~%, Central Nervous system drugs with ~%, Respiratory system drugs with ~%, Musculoskeletal system drugs with ~%, dermatology drugs with ~%, genitourinary and hormonal drugs with ~%, blood related drugs with ~%, oncology with ~% and rest of the therapeutic segments with ~% of the revenue share in 2017.


 
By Domestic and International Players: Domestic players have accounted for ~% of the revenue in Indonesia pharmaceutical market in 2017 driven by the implementation of JKN (National Health Insurance System) in 2014. International players have captured ~% of the revenue share in 2017 driven by favorable government norms for foreign ownership.


 
By Generic and Patented Drug: Generic drugs have accounted for the major revenue share of ~% in 2017 driven by the increased demand from government run hospitals and clinics. The share of patented drugs has increased from ~% in 2013 to ~% in 2017. Further, ethical generic drugs have accounted for ~% of the Indonesia generic drug market revenue in 2017 followed by free sale drugs with ~% and unbranded drug sale with ~%.


 
By OTC and Prescription Drugs: The Prescription drugs sales have accounted for ~% of the revenue share in Indonesia Pharmaceuticals Market. OTC drugs have accounted for ~% of the revenue share in 2017. This segment is driven by increased tendency of Indonesians to treat them and take self medication
By Domestic Sales and Exports: Domestic sales have accounted for a majority revenue share of ~% in 2017 whereas exports have accounted for a small share of ~%. The domestic market is dominated by the sale of low priced ethical generic medicines.


 
Indonesia Pharmaceutical Market Competition Overview
Indonesia Pharmaceutical market is dominated by domestic players which control ~% of the market in 2017. Recent favorable government regulations have facilitated the entry of foreign players in the space. There are 206 pharmaceutical companies (182 domestic and 24 international companies) located in Indonesia and ~% of them are located in Java in 2016. These players compete on the basis of distribution network, product portfolio, marketing activities and research and development. The domestic players dominate the generic drug and over the counter drug segment. International players have better expertise, skilled labor and infrastructure to produce such medicines at competitive prices. While domestic companies dominate the market for low cost generic drugs, multinational players have taken over high-demand, specialized segments and pharmaceuticals services ranging from capsule provision to instrumentation and packaging.


 
Indonesia Pharmaceutical Market Future Potential
Indonesia pharmaceutical industry is expected to increase from USD ~ billion in 2018 to USD ~ billion at a growth rate of ~%. The industry growth will be led by Indonesia’s large population and growing middle-income class, supportive government policies and higher investment in the industry. With the increase in incidence of communicable diseases such as HIV, TB, therapeutic segments such as anti infectives and respiratory are expected to grow. Major companies are expected to increase investment in nutritional and herbal medicines due to changing preference in the industry. Apart from manufacturing generic and patented drugs, pharmaceutical companies will shift focus to other niche segments such as combined dosages, novel drug delivery areas. Further in order to overcome the shortcomings, Contract Development and Manufacturing Organizations (CDMOs) will emerge as an attractive resource for manufacturers seeking to expand their capacities.


 
Key Topics Covered in the Report:


 

 
  • Indonesia Healthcare Market Size, 2012-2017

 
  • Indonesia Pharmaceutical Market Size, 2012-2017

 
  • Indonesia Pharmaceutical Market Segmentation (by therapeutic segment, by domestic and international players, by generic and patented drug, by OTC and prescription drugs, by domestic sales and exports and by region)

 
  • Trends and Developments in Indonesia Pharmaceutical Market

 
  • Issues and Challenges in Indonesia Pharmaceutical Market

 
  • Government Initiatives, Rules and Regulations in Indonesia Pharmaceutical Market

 
  • Indonesia Pharmaceutical Market Competitive Landscape

 
  • Indonesia Pharmaceutical Future Outlook and Projections, 2018-2022

 
  • Indonesia Healthcare Future Outlook and Projections, 2018-2022

 
  • Analyst Recommendations

 
  • Macro-economic Factors Impacting Indonesia Healthcare Market

 

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Diabetic Peripheral Neuropathy - Pipeline Review, H1 2020

Diabetic Peripheral Neuropathy - Pipeline Review, H1 2020

  • $ 2000
  • January 2020

Diabetic Peripheral Neuropathy - Pipeline Review, H1 2020SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Peripheral Neuropathy - Pipeline Review, H1 2020, provides an overview ...

Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H1 2020

Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H1 2020

  • $ 2000
  • January 2020

Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H1 2020SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H1 2020, provides ...

Respiratory Assist Devices - Medical Devices Pipeline Assessment, 2020

Respiratory Assist Devices - Medical Devices Pipeline Assessment, 2020

  • $ 4000
  • February 2020

Respiratory Assist Devices - Medical Devices Pipeline Assessment, 2020SummaryMedical Devices sector report, “Respiratory Assist Devices - Medical Devices Pipeline Assessment, 2020" provides an overview ...

Global Pharmerging Industry $ 4950 February 2020


ref:plp2018

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on